Last quarter (Q ), Theralink Technologies's total revenue was $83.95K, a decrease of -48.88% from the same quarter last year. In Q, Theralink Technologies's net income was $-19.05M. See Theralink Technologies’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 22	Sep 21	Sep 20	Dec 19	Dec 18
Total Revenue	$ 456.18K	$ 567.90K	$ 505.60K	$ 181.23K	$ 0.00	$ 0.00
Cost of Revenue	$ 77.61K	$ 224.89K	$ 117.46K	$ 52.59K	-	-
Gross Profit	$ 327.73K	$ 343.02K	$ 388.15K	$ 128.64K	-	-
Operating Expense	$ 1.36M	$ 11.98M	$ 5.95M	$ 3.49M	$ 1.77M	$ 1.78M
Operating Income	$ -716.68K	$ -11.64M	$ -5.57M	$ -3.36M	$ -1.77M	$ -1.78M
Net Non Operating Interest Income Expense	$ -14.51M	$ -1.09M	$ -121.09K	$ -31.22K	$ -1.80M	$ -2.13M
Other Income Expense	$ 2.99M	$ 7.30K	$ -238.11K	$ 217.74K	$ -5.84M	$ 10.38M
Pretax Income	$ -18.39M	$ -12.74M	$ -5.47M	$ -3.17M	$ -9.40M	$ 6.47M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	$ 9.92K	-	-	-
Net Income Common Stockholders	$ -18.49M	$ -12.98M	$ -6.64M	$ -5.18M	$ -9.40M	$ 6.47M
Basic EPS	-	-	-	$ -0.06	$ -19.00	$ 20.66
Diluted EPS	-	-	-	$ -0.06	$ -19.00	$ 9.09
Basic Average Shares	$ 18.45B	$ 5.88B	$ 5.37B	$ 84.66M	$ 494.84K	$ 311.81K
Diluted Average Shares	$ 33.45B	$ 5.88B	$ 5.37B	$ 84.66M	$ 494.84K	$ 708.70K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -1.19M	$ -12.21M	$ 6.07M	$ 3.54M	$ 1.77M	$ 1.78M
Net Income From Continuing And Discontinued Operation	$ -23.11M	$ -12.74M	$ -5.47M	$ -3.17M	$ -9.40M	$ 6.47M
Normalized Income	$ -26.45M	-	-	$ -3.38M	$ -3.56M	$ -1.11M
Interest Expense	-	-	-	$ 31.22K	$ 1.80M	$ 2.13M
EBIT	$ -3.88M	$ -11.65M	$ -5.35M	$ -3.14M	$ -7.61M	$ 8.60M
EBITDA	$ -11.36M	$ -10.72M	$ -5.10M	$ -3.04M	$ -7.60M	$ 8.60M

Currency in USD

Theralink Technologies Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing